Solomon, D. H., Demler, O., Rist, P. M., Santacroce, L., Tawakol, A., Giles, J. T., Liao, K. P., & Bathon, J. M. (2024). Biomarkers of Cardiovascular Risk in Patients With Rheumatoid Arthritis: Results From the TARGET Trial. Journal of the American Heart Association, 13(5). https://doi.org/10.1161/jaha.123.032095

Zureigat, H., Civieri, G., Abohashem, S., Osborne, M. T., Solomon, D. H., Giles, J. T., Bathon, J., Massarotti, E., Unizony, S., & Tawakol, A. (2024). Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis. Journal of Nuclear Cardiology, 33, 101813. https://doi.org/10.1016/j.nuclcard.2024.101813

Solomon, D. H., Giles, J. T., Liao, K. P., Ridker, P. M., Rist, P. M., Glynn, R. J., Broderick, R., Lu, F., Murray, M. T., Vanni, K., Santacroce, L. M., Abohashem, S., Robson, P. M., Fayad, Z., Mani, V., Tawakol, A., & Bathon, J. (2022). Reducing cardiovascular risk with immunomodulators: a randomised active comparator trial among patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 82(3), 324–330. https://doi.org/10.1136/ard-2022-223302